久久婷婷国产综合精品,久久久久久久性潮,换脸国产av一区二区三区,韩国精品一区二区三区无码视频 ,久久久久成人精品无码

  • Amryt’s Myalepta scores NICE backing for rare lipid disorder pharmatimes
    January 21, 2021
    The UK’s National Institute for Health and Care Excellence (NICE) has recommended Amryt Pharma’s Myalepta (metreleptin) for use within the NHS.
  • Green light for Amryt's epidermolysis bullosa study pharmatimes
    January 08, 2019
    An Independent Data Monitoring Committee (IDCM) has recommended that Amryt’s pivotal Phase III EASE trial for AP101 - a potential treatment for the currently incurable Epidermolysis Bullosa (EB) - should continue.
  • Amryt in-licenses novel gene therapy platform from UCD pharmatimes
    July 23, 2018
    UK biotech Amryt has secured itself access to a novel gene therapy platform that could give rise to a new treatment option for patients with Epidermolysis bullosa (EB), a group of rare inherited skin disorders that cause the skin to become very fragile.

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194
+86 15021993094

PharmaSources Customer Service